Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | KYNU | Q16719 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 12/20 | 0.50 |
| ▸ | MME | P08473 | 11/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23881669 | 0.89 | ATM (0.54) | ACE2KYNUECE1MMEELANE | |
| SCHEMBL23881726 | 0.89 | ECE1 (0.61) | ACE2KYNUECE1MME | |
| SCHEMBL23881801 | 0.89 | ACE2 (0.48) | ACE2KYNUECE1MME | |
| SCHEMBL23881692 | 0.89 | PTGES (0.46) | ACE2KYNUECE1MMEELANE | |
| SCHEMBL23881850 | 0.88 | ACE2 (0.50) | ACE2KYNUECE1MMEELANE | |
| SCHEMBL23881683 | 0.86 | MMP8 (0.52) | ACE2KYNUECE1MME | |
| SCHEMBL23881677 | 0.85 | F2 (0.49) | ACE2ECE1MMEELANEPRTN3 | |
| SCHEMBL23881757 | 0.85 | NPC1 (0.47) | ACE2KYNUECE1MMEELANE | |
| SCHEMBL23881721 | 0.85 | ACE2 (0.46) | ACE2ECE1MME | |
| SCHEMBL23881820 | 0.85 | MEN1 (0.47) | ACE2ECE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | ACE2 106/4885KYNU 473/4885ECE1 54/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | ACE2 106/4885KYNU 473/4885ECE1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.